Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anna Seto"'
Autor:
Mayur Narkhede, Nancy L. Bartlett, Sami Ibrahimi, Leslie Popplewell, Anna Seto, Jamie Bates, Yeonju Lee, Vaishnavi Ganti, Ling Han, Tianling Chen, Manish R. Patel
Publikováno v:
eJHaem, Vol 4, Iss 2, Pp 370-380 (2023)
Abstract Signal regulatory protein alpha (SIRPα) is the receptor for cluster of differentiation (CD)47, a potent “don't eat me” signal for macrophages. Disruption of CD47‐SIRPα signaling in the presence of prophagocytic signals can lead to en
Externí odkaz:
https://doaj.org/article/8470c6427c364eb6b41fe36383a68d9f
Autor:
Michael Gordon, Anthony W Tolcher, James Strauss, Marianna Zavodovskaya, Anna Seto, Tianling Chen, Susanna Stinson, Kathleen M Mahoney, Chia-Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M Jürgensmeier, Ahmed A Othman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions. This Phase 1 study (NCT03954704) evaluated the safety, p
Externí odkaz:
https://doaj.org/article/5b53ab91d2af465c92d22787a41dbfa2
Autor:
Michael Gordon, Anthony Tolcher, James Strauss, Rick Sorensen, Marianna Zavodovskaya, Ping Cheng Yi, Audrey Goddard, Matthew Peach, Kathleen Mahoney, Xiaoyun Yang, Kai-Wen Lin, Biao Li, Anna Seto, Tianling Chen, Juliane Jürgensmeier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/347886e0b29943a29b63e012d170d625
Autor:
Anjali Rohatgi, James Chih-Hsin Yang, Dong-Wan Kim, Molly Li, Joseph Park, Anna Seto, Jie Zhang, Nir Peled
Publikováno v:
Cancer Research. 83:CT049-CT049
Background: Single-agent chemotherapy is the standard of care (SOC) in pts with mNSCLC progressing on or after PT-based chemotherapy and CPI but is associated with poor outcomes. SG is a Trop-2-directed antibody-drug conjugate. SG monotherapy demonst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cea79773487abc1cb10715bd0763b0b
https://doi.org/10.1158/1538-7445.am2023-ct049
https://doi.org/10.1158/1538-7445.am2023-ct049
Autor:
Anthony W Tolcher, Michael Gordon, Kathleen M Mahoney, Anna Seto, Marianna Zavodovskaya, Chia-Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M Jürgensmeier, Susanna Stinson, Ahmed A Othman, Tianling Chen, James Strauss
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005267
BackgroundCluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions. This Phase 1 study (NCT03954704) evaluated the safety, ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1052fea7a49c1574b0b7cfe067176ebe
https://doi.org/10.1136/jitc-2022-005267
https://doi.org/10.1136/jitc-2022-005267
Autor:
Kathleen M. Mahoney, Audrey Goddard, Matthew Peach, Marianna Zavodovskaya, Michael S. Gordon, Rick Sorensen, James Strauss, Kai-Wen Lin, Xiaoyun Yang, Tianling Chen, Juliane Jürgensmeier, Anna Seto, Anthony W. Tolcher, Ping Cheng Yi, Biao Li
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundGS-1423 is a first-in-class bifunctional molecule comprised of an anti-CD73 antibody fused to the extracellular domain of TGFβ receptor II (TGFβRII). GS-1423 is designed to inhibit CD73-mediated adenosine production and neutralize active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d6eb96c80a8acdc2c2cf68dd8863129
https://doaj.org/article/347886e0b29943a29b63e012d170d625
https://doaj.org/article/347886e0b29943a29b63e012d170d625
Autor:
Michael J. Silverberg, Steven E. Gregorich, Megan J. Huchko, Anna Seto, Aileen Chi, Wendy A. Leyden, Shalini L Kulasingam, Miriam Kuppermann, George F. Sawaya, Karen Smith-McCune
Publikováno v:
Silverberg, MJ; Leyden, WA; Chi, A; Gregorich, S; Huchko, MJ; Kulasingam, S; et al.(2018). Human Immunodeficiency Virus (HIV)-and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia. OBSTETRICS AND GYNECOLOGY, 131(1), 47-55. doi: 10.1097/AOG.0000000000002371. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/03j8q7wm
Obstetrics and gynecology, vol 131, iss 1
Obstetrics and gynecology, vol 131, iss 1
Author(s): Silverberg, Michael J; Leyden, Wendy A; Chi, Aileen; Gregorich, Steven; Huchko, Megan J; Kulasingam, Shalini; Kuppermann, Miriam; Seto, Anna; Smith-McCune, Karen K; Sawaya, George F | Abstract: OBJECTIVE:To estimate the risk of cervical in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::427d87a00f7e137d2d153577c6c8bfd3
https://europepmc.org/articles/PMC5740002/
https://europepmc.org/articles/PMC5740002/
Autor:
Tianling Chen, Ian W. Flinn, Tycel Phillips, Andre Goy, Stephen D. Smith, Michael Wang, Wei Liang, Wojciech Jurczak, Wiesław Wiktor Jędrzejczak, Don A. Stevens, Morton Coleman, John M. Pagel, Tadeusz Robak, Jan Maciej Zaucha, Pier Luigi Zinzani, Charles M. Farber, Anna Seto, Kami J. Maddocks, Sun Ku Lee
Publikováno v:
Blood. 132:4144-4144
Background: MCL is a subtype of NHL that remains largely incurable with conventional therapies; BR is standard first-line therapy. Acalabrutinib is a potent, highly selective, covalent Bruton tyrosine kinase inhibitor with minimal off-target activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d9a0c57acd5821e21bbbf90374ca549
https://doi.org/10.1182/blood-2018-99-110617
https://doi.org/10.1182/blood-2018-99-110617
Autor:
Silverberg, Michael J., Leyden, Wendy A., Chi, Aileen, Gregorich, Steven, Huchko, Megan J., Kulasingam, Shalini, Kuppermann, Miriam, Anna Seto, Smith-McCune, Karen K., Sawaya, George F., Seto, Anna
Publikováno v:
Obstetrics & Gynecology; Jan2018, Vol. 131 Issue 1, p47-55, 9p